Lucid Diagnostics (LUCD) to Release Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $1.30 million for the quarter.

Lucid Diagnostics Stock Down 0.4%

NASDAQ:LUCD traded down $0.01 during trading hours on Monday, hitting $1.13. 396,910 shares of the company's stock traded hands, compared to its average volume of 484,029. The firm has a market cap of $118.56 million, a P/E ratio of -0.99 and a beta of 1.28. Lucid Diagnostics has a 52 week low of $0.68 and a 52 week high of $1.80. The business's fifty day simple moving average is $1.36 and its two-hundred day simple moving average is $1.12.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Needham & Company LLC restated a "buy" rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Friday, April 11th. BTIG Research set a $2.00 target price on Lucid Diagnostics in a report on Tuesday, March 25th. Ascendiant Capital Markets upped their target price on Lucid Diagnostics from $7.00 to $7.50 and gave the stock a "buy" rating in a report on Monday, April 21st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $2.00 target price on shares of Lucid Diagnostics in a report on Wednesday, March 26th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $3.50.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.